Circulating RNAs in Acute Congestive Heart Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-08-17

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this American Heart Association-funded and NIH-funded study is to examine circulating RNAs in the acute CHF setting, how they change with decongestive therapy, and their function in vitro and in vivo.

The investigators are testing the hypothesis that ex-RNA levels change significantly during decongestion therapy and can be used as a marker of those individuals who respond to CHF therapy (in terms of cardiac structure or outcome). Additionally, the translational research design allows the investigators to assay the effects of these RNAs on tissue phenotypes in vitro.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CMR Assessment of Cardiac Microvascular Dysfunction in Patients With HFpEF

NCT06316661

Microvascular Coronary Artery Disease Heart Failure With Reduced Ejection Fraction

RECRUITING

Understanding the Mechanisms of Diastolic Dysfunction

NCT03340233

Heart Failure With Preserved Ejection Fraction Healthy

WITHDRAWN NA

Cardiac MRI-Derived Pressure-Volume Loop Analysis in Heart Failure With Preserved Ejection Fraction

NCT07326605

Heart Failure With Preserved Ejection Fraction (HFPEF)

ENROLLING_BY_INVITATION

New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT04600115

MRI Scans

UNKNOWN EARLY_PHASE1

MRI Assessment of Patient Suitability for Cardiac Resynchronization Therapy (CRT)

NCT02728336

Cardiac Resynchronization Therapy Magnetic Resonance Imaging (MRI)

SUSPENDED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Nearly 5 million people in the United States have congestive heart failure (CHF). Although medical therapy such as beta-blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs) and aldosterone antagonists has improved prognosis, the overall rate of hospital admissions has continued to rise in the last decade and the mortality for patients with symptomatic heart failure remains worse than the majority of cancers in this country. Accordingly, significant opportunities exist for the improvement in outcomes of patients with CHF, both from a morbidity and mortality standpoint. Such opportunities may lie in the outpatient medical management of patients with CHF. Specifically acute CHF represents a particularly underserved area of CHF care.

In this regard, the investigative group and others have demonstrated the utility of extracellular RNAs (short, 20-22 nucleotide RNA molecules stable in circulation in humans) to predict cardiac structural changes and fibrosis in patients post-myocardial infarction with significant changes in cardiac structure. However, little has been done looking at the acute CHF setting. Specific questions include:

1. What RNAs change in the acute CHF setting, and how do these change over time with diuretic therapy?
2. Are these changes in RNA functional? That is, do they cause characteristic changes in the heart in vitro and on heart phenotypes in patients?
3. Do these RNAs predict outcomes in long-term follow-up?

To answer these questions, the investigators will enroll patients who are currently admitted at MGH or BIDMC with acute CHF. The study protocol involves:

1. Venous blood draw, 40 ml anytime within their hospitalization
2. Venous blood draw, 40 ml within 48 hours of planned hospital discharge
3. Venous blood draw, 40 ml at follow-up (within one year of discharge)

Eligible patients (e.g., absence of standard MRI contraindications, GFR \> 40ml/min/1.73m2) will be asked pre-discharge or by telephone contact after discharge about coming in for a cardiac MRI study at any point within one year of discharge to examine cardiac structure/function and fibrosis. MRI imaging will be performed by Partners investigators (Dr. Ravi Shah, Dr. Michael Steigner, Dr. Michael Jerosch-Herold) at the 221 Longwood BRIC Imaging Facility (at the Brigham and Women's Hospital, BWH).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Congestive Heart Failure Heart Failure With Reduced Ejection Fraction Heart Failure With Normal Ejection Fraction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with HF-rEF

These patients have Heart Failure with Reduced Ejection Fraction (EF \< 55% per the protocol).

Cardiac MRI

Intervention Type DIAGNOSTIC_TEST

Cardiac MRI is a test that allows us to look at how the heart muscle works and the amount of scar tissue in your heart. Screening questions will be asked to make sure that patients are not pregnant, and that they have kidney function tests to confirm that IV contrast used (gadolinium) during the MRI is safe for them.

Patients with HF-pEF

These patients have Heart Failure with Preserved Ejection Fraction (EF \> 55% per the protocol).

Cardiac MRI

Intervention Type DIAGNOSTIC_TEST

Cardiac MRI is a test that allows us to look at how the heart muscle works and the amount of scar tissue in your heart. Screening questions will be asked to make sure that patients are not pregnant, and that they have kidney function tests to confirm that IV contrast used (gadolinium) during the MRI is safe for them.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cardiac MRI

Cardiac MRI is a test that allows us to look at how the heart muscle works and the amount of scar tissue in your heart. Screening questions will be asked to make sure that patients are not pregnant, and that they have kidney function tests to confirm that IV contrast used (gadolinium) during the MRI is safe for them.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age \>/= 18 years of age
2. Assessment of LV function within the last year or planned during hospital admission
3. Acute CHF diagnosis, requiring clinical signs and/or symptoms (including exertional or rest dyspnea, orthopnea or PND) AND

1. N-terminal pro-BNP level \> 1000 pg/ml or BNP \> 400 pg/ml, OR
2. Clinical evidence of congestion:

* X-ray evidence of pulmonary edema or pleural effusions
* Elevated JVP, lower extremity edema, or rales on pulmonary examination
* Right heart catheterization evidence of elevated filling pressures (RA pressure \> 10 mmHg; PCWP \> 18 mmHg)
4. Clinical response to IV diuretic therapy (as judged by a physician)

Exclusion Criteria

1. Hematocrit at time of consent \< 30%
2. End-stage non-cardiovascular diseases

1. Known HIV/AIDS
2. Cirrhosis
3. Hemodialysis-dependent renal failure
3. Pregnancy (as adjudicated by patient history)
4. Ventricular assist device support
5. Acute mechanical support on admission
6. Post-heart transplant
7. Malignancy within the last 1 year or clinically active rheumatologic or autoimmune illnesses

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No